Vaxeal’s cancer immunotherapy portfolio is the result of 20 years of research and is unique in the biopharmaceutical sector.
Recent scientific research has produced an exciting opportunity to develop advanced immunotherapies to treat cancers. Consistent human data has shown that cancer immunotherapies are overcoming both efficacy issues, by targeting specific cancer biomarkers, and safety issues, by limiting toxicity and immune-related adverse events induced by immune checkpoint blockades and standard of care therapies.
The central aim of all cancer immunotherapies is the induction of effective anti-tumor immunity in cancer patients leading to the elimination of tumors and long-lasting protection against relapses. Vaxeal is developing game-changing immunotherapies that meet the growing need for these improved treatments. Over 20 million new cases of cancer are predicted by 2025, compared with the recorded 12 million in 2008.
With this scenario, global sales of cancer drugs will grow significantly, surpassing US$100 billion by 2020. Immunotherapies are expected to lead this market growth.
Vaxeal is the convergence point for a diverse advanced expertise in tumor immunology and vaccine formulation, including predictive T-cell assays, ex-vivo assessment of T-cell responses in cancer patients, new relevant pre-clinical animal models, as well as optimal vaccine formulation.
Proprietary long synthetic peptide SVX-1 and CBX-1 vaccines, targeting broadly expressed tumour antigens, Survivin and Cyclin B-1, have been assessed for their immunogenicity in relevant preclinical models.